SUPPLY AND LICENSE AGREEMENT BETWEEN GEMA Biotech S.A. San Vladimiro 3056, San Isidro, Province of Buenos Aires, Argentina AND Serendex ApS CVR 3053 2228 Slotsmarken 12,1 2970 Horsholm DenmarkSupply and License Agreement • February 10th, 2017 • Mast Therapeutics, Inc. • Pharmaceutical preparations
[***] Indicates that information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
Execution versionSupply Agreement • February 10th, 2017 • Mast Therapeutics, Inc. • Pharmaceutical preparations • New York
[***] Indicates that information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
BUSINESS TRANSFER AGREEMENT relating to the business of Serendex Pharmaceuticals A/S (Company Reg. No. (CVR) 30532229) Pharmaorigin ApS (Company Reg. No. (CVR) 29178291) Drugrecure ApS (Company Reg. No. (CVR) 29154406) JKM/JKM/1037031Business Transfer Agreement • February 10th, 2017 • Mast Therapeutics, Inc. • Pharmaceutical preparations
ContractSupply Agreement • February 10th, 2017 • Mast Therapeutics, Inc. • Pharmaceutical preparations • Texas
[***] Indicates that information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
EXECUTION COPY COMMERCIAL SUPPLY AGREEMENTCommercial Supply Agreement • February 10th, 2017 • Mast Therapeutics, Inc. • Pharmaceutical preparations
This COMMERCIAL SUPPLY AGREEMENT (“Agreement”), dated as of 24 April 2015 (“Effective Date”), is made between PARI Pharma GmbH, a German corporation, with a principal place of business at Moosstrasse 3, D-82319 Starnberg, Germany (“PARI”), and Serendex, Pharmaceuticals A/S, Slotsmarken 17, 2.tv., DK-2970 Horsholm, Denmark (“Serendex”). PARI and Serendex are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
October 1st, 2009Employment Agreement • February 10th, 2017 • Mast Therapeutics, Inc. • Pharmaceutical preparations
Savara Inc. (“Company”) is pleased to offer you the position of Executive Vice President initially reporting to me Robert Neville, Executive Chairman. Your anticipated starting date will be October 1st, 2009. Your employment relationship will be subject to the terms and conditions of this agreement.
SAVARA INC. STOCK OPTION PLAN INCENTIVE STOCK OPTION AGREEMENTIncentive Stock Option Agreement • February 10th, 2017 • Mast Therapeutics, Inc. • Pharmaceutical preparations • Texas
AGREEMENT between Savara Inc. (the “Company”), and the above named Optionee (“Optionee”), an employee, consultant or director of the Company.
Execution Copy RESEARCH COLLABORATION AND LICENSE AGREEMENTResearch Collaboration and License Agreement • February 10th, 2017 • Mast Therapeutics, Inc. • Pharmaceutical preparations
This Research Collaboration and License Agreement (this “Agreement”) is made effective as of 7th day of November 2014, (the “Effective Date”) by and between Serendex Pharmaceuticals A/S, Slotsmarken 17, 2.tv., DK-2970 Hørsholm, Denmark (“Serendex”), and PARI Pharma GmbH, Moosstrabe 3, D-82319 Starnberg, Germany (“PARI”). Each of Serendex and PARI is a “Party” hereto and collectively they are the “Parties”.
STOCK ISSUANCE AGREEMENTStock Issuance Agreement • February 10th, 2017 • Mast Therapeutics, Inc. • Pharmaceutical preparations • Texas
THIS STOCK ISSUANCE AGREEMENT (this “Agreement”) is made as of the day of by and between Savara Inc., a Delaware corporation (the “Company”), and (the “Stockholder”).
